Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.56 USD | -1.10% | +1.22% | -13.12% |
10/05 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
10/05 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.12% | 9.13TCr | |
+29.88% | 68TCr | |
+30.35% | 59TCr | |
-3.73% | 36TCr | |
+17.69% | 33TCr | |
+3.15% | 28TCr | |
+15.53% | 24TCr | |
+10.16% | 21TCr | |
-8.14% | 20TCr | |
+7.39% | 17TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating